Table.
TDF/FTC | TAF/FTC | |
---|---|---|
Effectiveness* | ||
MSM and transgender women | ~99% | ~99% |
Heterosexual women and men | ~99% | Unknown |
People who inject drugs | 74-84% | Unknown |
Changes in safety parameters at 48 weeks(4, 9) | ||
Estimated glomerular filtration rate, mean (mL/min) | −2.0 | +2.0 |
Hip bone mineral density, mean (%) | −1.0 | +0.2 |
Fasting low-density lipoprotein, median (mg/dL) | −6.5 | +1.0 |
Body weight, mean (kg) | 0 | +1.1 |
Cost | ||
Average wholesale price per month | $2,110 | $2,110 |
Generic version available | 2020 | 2022 to 2025 |
TDF/FTC, tenofovir disoproxil fumarate with emtricitabine; TAF/FTC, tenofovir alafenamide with emtricitabine.
Effectiveness estimates for TDF/FTC are from the Centers for Disease Control and Prevention (https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html).